Safety and efficacy of immune checkpoint inhibitors in patients with triple-negative breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are under extensive investigation as a treatment for triple-negative breast cancer (TNBC) in numerous trials. Given the need to evaluate their therapeutic profile, we conducted this systematic review and meta-analysis to comprehensively assess the safety and efficacy of ICI therapy for TNBC.

Methods

We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published in English from inception to March 10, 2024. Primary endpoints included treatment-related adverse events (trAEs) of any grade and Grade ≥ 3, as well as immune-related adverse events (irAEs).

Results

Thirteen RCTs involving 5,890 TNBC patients were included in the meta-analysis. ICI treatment was associated with

SUBMITTER: Yan X 

PROVIDER: S-EPMC12639917 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature